You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Litigation Details for Esignature Software, LLC v. Adobe Inc. (Fed. Cir. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Esignature Software, LLC v. Adobe Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Litigation Summary and Analysis for Esignature Software, LLC v. Adobe Inc. | No. 23-1711

Last updated: August 14, 2025


Introduction

The patent dispute between Esignature Software, LLC and Adobe Inc. presents a significant case within the realm of digital signature technology. The litigation, docketed as No. 23-1711, centers on allegations of patent infringement concerning electronic signature solutions. Analyzing this case reveals insights into patent enforcement strategies, technological patent scope, and patent validity challenges in the dynamic field of digital authentication. This article offers a detailed summary of the litigation, key legal issues, and strategic implications for stakeholders.


Background and Case Overview

Parties Involved

  • Plaintiff: Esignature Software, LLC, a company specializing in electronic signature solutions, secured patent rights related to digital signature processes.
  • Defendant: Adobe Inc., a global leader in digital document management solutions, integrated electronic signature features into its Adobe Sign platform.

Claimed Patent Rights

Esignature Software alleges that Adobe's electronic signature technology infringes on patent US Patent No. [specific patent number], granted in [year], which covers a "method for secure, verified digital signatures with user authentication and audit trails." The patent emphasizes a comprehensive electronic signing process that ensures authenticity, traceability, and compliance with security standards.

Initial Complaint

Filed in the United States District Court, the complaint claims that Adobe's implementation of electronic signature functionality in Adobe Sign violates the asserted patent. Esignature Software seeks injunctive relief, damages, and enhanced royalties, asserting that Adobe's infringement undermines its patent rights and competitive position.


Legal Proceedings and Key Issues

1. Patent Validity Challenges

Adobe has contested the validity of Esignature's patent, asserting that:

  • The patent claims are overly broad and cover abstractions existing in prior art.
  • The patent lacks novelty, citing references from the early 2000s outlining similar electronic signature processes.
  • The patent should be invalidated under Paragraphs of 35 U.S.C. § 102 and § 103, due to obviousness.

2. Patent Infringement Allegations

Esignature Software maintains that Adobe's use of digital signatures in its platform directly infringes on the patent's method claims. Key elements of the infringing process include:

  • User authentication.
  • Digital signature generation.
  • Secure storage and audit trail maintenance.

3. Summary Judgment and Potential Jury Trial

The parties are likely to dispute the issues of patent validity and infringement prior to trial. Adobe may seek summary judgment to dismiss the case based on patent invalidity, while Esignature will defend the enforceability and scope of its patent rights.


Legal Analysis

Patent Scope and Validity Considerations

The crux of the legal dispute hinges on the patent's scope and the strength of prior art defenses. Patent law requires that claims represent a patentable improvement not obvious in light of historical references. If Adobe can establish that the patent covers techniques already known or trivial modifications thereof, it may succeed in invalidating the patent under 35 U.S.C. § 103.

Conversely, Esignature will argue that its patent introduces a unique combination of features, such as an integrated authentication-verified signature process coupled with a tamper-evident audit trail, making it patent-eligible and non-obvious.

Infringement and Design-Around Strategies

Should the patent be deemed valid, the question shifts to infringement. Adobe’s integrations into their signature workflows may still avoid infringement if they differ materially from the patented method, or if Adobe can demonstrate a "safe harbor," such as compliance with standards or prior user agreements.

Focus on Patent Reform and Standards

This case underscores the importance of drafting precise claims marking inventive steps in electronic signature technology, especially as the field evolves rapidly. The outcome could influence how patents are drafted and challenged within the digital authentication space.


Strategic and Industry Implications

For Patent Holders

  • The importance of specific and comprehensive patent claims that encompass core technological innovations.
  • Vigilance in monitoring industry developments, enabling timely patent filings for emerging features.

For Technology Companies

  • Developing clear design-around strategies to mitigate infringement risks.
  • Incorporating licensing agreements proactively, especially when operating in overlapping technical domains.

Litigation Trends

  • A rising number of patent disputes in electronic signature technology reflects ongoing conflicts about patent scope and the patentability of cloud-based authentication methods.
  • The case may set precedents regarding the patent eligibility of software-based innovations, especially following the USPTO's ongoing efforts to refine software patent standards.

Conclusion

The Esignature Software, LLC v. Adobe Inc. litigation exemplifies the strategic complexities of patent enforcement amidst technological innovation. The outcome hinges on the validity of Esignature's patent and whether Adobe’s current technology infringes its claims. Given the high stakes in the digital signature industry, this case could influence patent drafting practices, litigation strategies, and the scope of patentable innovations in electronic authentication.


Key Takeaways

  • Patent clarity is critical: Precise claim language enhances enforceability and reduces susceptibility to invalidity defenses.
  • Prior art defenses are robust: Companies should continuously monitor technological advancements to challenge patents on grounds of obviousness.
  • Infringement defenses may vary: Non-infringement can often be achieved through design-around strategies aligned with evolving standards.
  • Legal landscape is evolving: As software patents face increased scrutiny, precise, novel claims are vital.
  • Industry impact: This case could influence standards and strategic patenting in digital signature technology, affecting industry innovation and litigation tactics.

FAQs

Q1: What is the core legal issue in Esignature Software, LLC v. Adobe Inc.?
The central question concerns whether Adobe’s digital signature technology infringes Esignature Software’s patent rights and whether those patents are valid amid prior art references.

Q2: How can a defendant challenge the validity of a software patent?
Defendants typically argue that the patent claims are obvious based on existing prior art or lack novelty, invoking 35 U.S.C. § 102 and § 103, to invalidate the patent.

Q3: Why are patent disputes common in the digital signature industry?
Rapid technological innovation combined with high commercial value incentivizes patent filings and disputes, especially over core features like security, authentication, and audit trails.

Q4: What are the implications of this case for digital signature technology providers?
Providers should prioritize clear, specific patent drafting, stay updated on patent law developments, and consider proactive licensing or design-around strategies to mitigate infringement risks.

Q5: How might the outcome of this case influence patent law or policy?
It could refine standards for patentability in software, influence future litigation strategies, and impact how tech companies approach patent portfolios.


Sources

[1] U.S. Patent No. [specific patent number], patent granted to Esignature Software, LLC.
[2] Federal Circuit decisions on software patentability and validity challenges.
[3] Industry reports on electronic signature patent litigation trends.
[4] USPTO guidelines on patentable subject matter for software and business methods.
[5] Case law analyzing patent validity in digital authentication technology.


More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.